Merck & Co., Inc. (MRK)
Merck & Co., Inc. (MRK) Presents at TD Cowen 45th Annual Health Care Conference (Transcript)
Start Time: 14:30 January 1, 0000 3:05 PM ET Merck & Co., Inc.
These S&P 500 Stocks Have Low P/E Ratios — Time to Buy?
Purchasing stocks at the right time can maximize your return on investment, especially if you plan to buy and hold shares toward a short-term or medium-term financial goal. A stock's P/E ratio can give you an immediate idea of whether a stock is trading at, below or above fair value.
Merck (MRK) Exceeds Market Returns: Some Facts to Consider
Merck (MRK) closed the most recent trading day at $92.25, moving +1.84% from the previous trading session.
Merck Slips 8% in a Month: Should You Buy, Hold or Sell the Stock?
We believe investors with a long-term horizon should stay invested in MRK stock, while short-term investors should consider selling the same.
Merck's Oncology Strength: Beating Wall Street Again
On February 4, Merck released financial results for Q4 2024, which, as in previous quarters, once again beat analysts' expectations. This was driven by a strong performance by its oncology franchise, which posted sales of $8.73 billion, up 19.7% from Q4 2023 and 5.7% from Q3 2024. Thanks in part to the label expansions for Keytruda, its sales grew by 18.6% year on year.
US drugmaker Merck to boost workforce in India, executive says
Drugmaker Merck , known as MSD outside of the U.S. and Canada, expects to increase its workforce across its India sites by the end of the year, a senior company executive said on Wednesday.
Merck expects cancer therapy Keytruda to be part of government price setting in 2026
Drugmaker Merck said on Tuesday it expects its top selling cancer therapy Keytruda to be selected in 2026 for government price setting, which would become effective on January 1, 2028.
Wall Street Analysts See Merck (MRK) as a Buy: Should You Invest?
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Is Merck Stock a Buy?
It's been a rough start to 2025 for Merck (MRK 2.08%) shareholders following a less-than-stellar fourth-quarter earnings report. Even as the pharmaceutical giant exceeded Wall Street estimates with 7% revenue growth and earnings per share (EPS) of $1.72 for the quarter ended Dec. 31, weak sales in China and soft forward guidance were seen as a disappointment.
Why Merck (MRK) is a Great Dividend Stock Right Now
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes?
I'm Buying Discounted Dividend Icons Up To 6% Yield
Great dividend stocks should offer a mix of durability, solid income generation, and growth prospects. In this article, I highlight 2 such names, both of which are trading at discounted valuations compared to historical norms. Both offer high yields and carry strong balance sheets, making them dividend juggernauts worth considering for potentially strong total returns.
Exclusive: Merck vaccine case linked to HHS Secretary Kennedy delayed, company says
Merck and a woman suing the drugmaker agreed to halt a trial over alleged injuries from the drugmaker's human papillomavirus vaccine in a case with ties to U.S. Department of Health and Human Services Secretary Robert F. Kennedy Jr, the company said.
